T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides

Autor: Steven P. Richieri, Joseph A. Markenson, Eric L. Matteson, Joseph M. Cash, Larry W. Moreland, Cornelia M. Weyand, William J. Koopman, Christopher J. Nardo, Leonard H. Calabrese, Joan M. Bathon, Elizabeth E Morgan, Dennis J. Carlo, Steven W. Brostoff, K. M. Uramoto, Thomas C. Adamson, Alan K. Matsumoto, Jocelyn P. Diveley, Zdenka Fronek, Louis W. Heck, Vibeke Strand
Rok vydání: 1998
Předmět:
Zdroj: Arthritis & Rheumatism. 41:1919-1929
ISSN: 1529-0131
0004-3591
Popis: OBJECTIVE Restricted T cell receptor (TCR) gene usage has been demonstrated in animal models of autoimmune disease and has resulted in the successful use of TCR peptide therapy in animal studies. This clinical trial was undertaken to determine the safety and efficacy of a combination of Vbeta3, Vbeta14, and Vbeta17 TCR peptides in Freund's incomplete adjuvant (IFA) in patients with rheumatoid arthritis (RA). METHODS A double-blind, placebo-controlled, multicenter, phase II clinical trial was undertaken using IR501 therapeutic vaccine, which consists of a combination of 3 peptides derived from TCRs (Vbeta3, Vbeta14, and Vbeta17) in IFA. A total of 99 patients with active RA received either 90 microg (n = 31) or 300 microg (n = 35) of IR501 or IFA alone (n = 33) as a control. The study medication and placebo were administered as a single intramuscular injection (1 ml) at weeks 0, 4, 8, and 20. RESULTS Treatment with IR501 was safe and well tolerated. None of the patients discontinued the trial because of treatment-related adverse events. Efficacy was measured according to the American College of Rheumatology 20% improvement criteria. Using these criteria, patients in both IR501 dosage groups showed improvement in disease activity. In the most conservative analysis used to evaluate efficacy, an intent-to-treat analysis including all patients who enrolled, the 90-microg dosage group showed a statistically significant improvement compared with control patients at the 20-week time point after the third injection. Trends toward improvement were shown in both the 90-microg and the 300-microg dosage groups at week 24 after the fourth injection. CONCLUSION IR501 therapeutic vaccine therapy was safe and well tolerated, immunogenic, and demonstrated clinical improvement in RA patients. Additional clinical trials are planned to confirm and extend these observations.
Databáze: OpenAIRE
Externí odkaz: